News

TOKYO, January 24, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Astellas and Sandoz AG (“Sandoz”) have entered into an Asset Purchase Agreement, under which Astellas will transfer the world wide product rights for antifungal agent MYCAMINE® (micafungin sodium/product name in Japan: FUNGUARD®). Once the transaction closes, Sandoz...

TOKYO, January 20, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on January 19th for the FORTIS Ph1/2 clinical trial evaluating the safety, tolerability and efficacy of investigational AT845 in adults with late-onset Pompe disease (LOPD). “With that same...

Data shows investigational zolbetuximab reduced risk of progression or death by 24.9% Study evaluated patients with Claudin 18.2-positive, HER2-negative locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma Data to be featured in late-breaking oral presentation TOKYO, Jan. 19, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D...

TOKYO, January 19, 2023 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the Science Based Targets initiative (SBTi)*1 has validated and approved its greenhouse gas (GHG) emissions reduction targets. The targets, as a science-based initiative, have been approved towards achieving the 1.5 degrees Celsius and well-below 2 degrees Celsius...